ALBERTDAVD Overzicht aandelen
Albert David Limited produceert en verhandelt farmaceutische formuleringen, infuusoplossingen, doseringsvormen op basis van kruiden en medicijnen in bulk in India. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 4/6 |
Beloningen
Risicoanalyse
Albert David Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹1,319.90 |
| 52 Week Hoogtepunt | ₹1,753.95 |
| 52 Week Laag | ₹911.05 |
| Bèta | 0.40 |
| 11 maand verandering | -2.69% |
| 3 maanden verandering | 8.31% |
| 1 Jaar Verandering | 44.60% |
| 33 jaar verandering | 121.16% |
| 5 jaar verandering | 227.32% |
| Verandering sinds IPO | 322.71% |
Recent nieuws en updates
Recent updates
A Piece Of The Puzzle Missing From Albert David Limited's (NSE:ALBERTDAVD) 26% Share Price Climb
Aug 31
Albert David (NSE:ALBERTDAVD) Is Increasing Its Dividend To ₹11.50
Jul 30Albert David (NSE:ALBERTDAVD) Has Announced That It Will Be Increasing Its Dividend To ₹11.50
Jul 16We Think That There Are Issues Underlying Albert David's (NSE:ALBERTDAVD) Earnings
May 21Positive Sentiment Still Eludes Albert David Limited (NSE:ALBERTDAVD) Following 25% Share Price Slump
Mar 20The Market Lifts Albert David Limited (NSE:ALBERTDAVD) Shares 33% But It Can Do More
Jan 20Albert David (NSE:ALBERTDAVD) Will Pay A Dividend Of ₹9.00
Jul 04Albert David (NSE:ALBERTDAVD) Is Paying Out A Dividend Of ₹9.00
May 22Here's Why We Think Albert David (NSE:ALBERTDAVD) Is Well Worth Watching
Feb 14We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Albert David Limited's (NSE:ALBERTDAVD) CEO For Now
Sep 08Calculating The Intrinsic Value Of Albert David Limited (NSE:ALBERTDAVD)
Feb 06Do Fundamentals Have Any Role To Play In Driving Albert David Limited's (NSE:ALBERTDAVD) Stock Up Recently?
Jan 22
Why Albert David's (NSE:ALBERTDAVD) CEO Pay Matters
Jan 07Have Insiders Been Buying Albert David Limited (NSE:ALBERTDAVD) Shares?
Dec 23Here's Why Albert David's (NSE:ALBERTDAVD) Statutory Earnings Are Arguably Too Conservative
Dec 08Should You Or Shouldn't You: A Dividend Analysis on Albert David Limited (NSE:ALBERTDAVD)
Nov 23A Look At The Intrinsic Value Of Albert David Limited (NSE:ALBERTDAVD)
Nov 08Should Weakness in Albert David Limited's (NSE:ALBERTDAVD) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Oct 13Is Now The Time To Put Albert David (NSE:ALBERTDAVD) On Your Watchlist?
Sep 28What Does Albert David's (NSE:ALBERTDAVD) CEO Pay Reveal?
Sep 13Are Insiders Buying Albert David Limited (NSE:ALBERTDAVD) Stock?
Aug 28Should You Buy Albert David Limited (NSE:ALBERTDAVD) For Its Dividend?
Aug 10A Look At The Fair Value Of Albert David Limited (NSE:ALBERTDAVD)
Aug 10Albert David Limited (NSE:ALBERTDAVD) Might Not Be As Mispriced As It Looks
Jul 20Rendement voor aandeelhouders
| ALBERTDAVD | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | -4.5% | -3.2% | -3.4% |
| 1Y | 44.6% | 42.8% | 27.4% |
Rendement versus industrie: ALBERTDAVD overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 42.8 % opleverde.
Rendement versus markt: ALBERTDAVD overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 27.4 %.
Prijsvolatiliteit
| ALBERTDAVD volatility | |
|---|---|
| ALBERTDAVD Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stabiele aandelenkoers: ALBERTDAVD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van ALBERTDAVD is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1938 | 1,497 | Umesh Kunte | www.albertdavidindia.com |
Albert David Limited produceert en verhandelt farmaceutische formuleringen, infuusoplossingen, plantaardige doseringsvormen en bulkgeneesmiddelen in India. Het biedt formuleringen voor parenterale, orale/entale, topische middelen en gezichtsverzorgingsproducten. Het bedrijf exporteert zijn producten naar Latijns-Amerika, Zuidoost-Azië en andere Afrikaanse landen.
Albert David Limited Samenvatting
| ALBERTDAVD fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹7.62b |
| Inkomsten(TTM) | ₹685.47m |
| Inkomsten(TTM) | ₹3.79b |
11.1x
Koers/Winstverhouding2.0x
P/S-verhoudingIs ALBERTDAVD overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ALBERTDAVD resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹3.79b |
| Kosten van inkomsten | ₹1.23b |
| Brutowinst | ₹2.55b |
| Overige uitgaven | ₹1.87b |
| Inkomsten | ₹685.47m |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 120.11 |
| Brutomarge | 67.42% |
| Nettowinstmarge | 18.11% |
| Schuld/Eigen Vermogen Verhouding | 0.6% |
Hoe presteerde ALBERTDAVD op de lange termijn?
Bekijk historische prestaties en vergelijking